TRANSACTUAL CIC

Company limited by guarantee

Company Registration Number:
12772196 (England and Wales)

Unaudited statutory accounts for the year ended 31 July 2023

Period of accounts

Start date: 1 August 2022

End date: 31 July 2023

TRANSACTUAL CIC

Contents of the Financial Statements

for the Period Ended 31 July 2023

Directors report
Balance sheet
Additional notes
Balance sheet notes
Community Interest Report

TRANSACTUAL CIC

Directors' report period ended 31 July 2023

The directors present their report with the financial statements of the company for the period ended 31 July 2023

Principal activities of the company

The company's principal activity during the year continued to be educational services.



Directors

The directors shown below have held office during the whole of the period from
1 August 2022 to 31 July 2023

Helen Clare Belcher
Chay Brown
jane francesca fae
Maryam Din


The director shown below has held office during the period of
1 August 2022 to 27 March 2023

Rico Jacob Alexander Young


The director shown below has held office during the period of
17 June 2023 to 31 July 2023

Kenye Rowe Walker


The above report has been prepared in accordance with the special provisions in part 15 of the Companies Act 2006

This report was approved by the board of directors on
5 April 2024

And signed on behalf of the board by:
Name: Helen Clare Belcher
Status: Director

TRANSACTUAL CIC

Balance sheet

As at 31 July 2023

Notes 2023 2022


£

£
Fixed assets
Tangible assets: 3 1,133 816
Total fixed assets: 1,133 816
Current assets
Debtors: 4 1,750 350
Cash at bank and in hand: 43,789 42,831
Total current assets: 45,539 43,181
Creditors: amounts falling due within one year: 5 ( 23,792 ) ( 37,807 )
Net current assets (liabilities): 21,747 5,374
Total assets less current liabilities: 22,880 6,190
Total net assets (liabilities): 22,880 6,190
Members' funds
Profit and loss account: 22,880 6,190
Total members' funds: 22,880 6,190

The notes form part of these financial statements

TRANSACTUAL CIC

Balance sheet statements

For the year ending 31 July 2023 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen not to file a copy of the company's profit and loss account.

This report was approved by the board of directors on 5 April 2024
and signed on behalf of the board by:

Name: Helen Clare Belcher
Status: Director

The notes form part of these financial statements

TRANSACTUAL CIC

Notes to the Financial Statements

for the Period Ended 31 July 2023

  • 1. Accounting policies

    Basis of measurement and preparation

    These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

    Turnover policy

    Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from donations and grants receivedand from the rendering of services. Turnover from donations and grants received is recognised when the funds have been received. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.

    Tangible fixed assets depreciation policy

    Tangible fixed assets are measured at cost less accumulative depreciation and any accumulative impairment losses. Depreciation is provided on all tangible fixed assets, other than freehold land, at rates calculated to write off the cost, less estimated residual value, of each asset evenly over its expected useful life, as follows:Office equipment - over 3 years

    Other accounting policies

    DebtorsShort term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.CreditorsShort term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.TaxationA current tax liability is recognised for the tax payable on the taxable profit of the current and past periods. A current tax asset is recognised in respect of a tax loss that can be carried back to recover tax paid in a previous period. Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.ProvisionsProvisions (ie liabilities of uncertain timing or amount) are recognised when there is an obligationat the reporting date as a result of a past event, it is probable that economic benefit will be transferred to settle the obligation and the amount of the obligation can be estimated reliably.

TRANSACTUAL CIC

Notes to the Financial Statements

for the Period Ended 31 July 2023

  • 2. Employees

    2023 2022
    Average number of employees during the period 5 0

TRANSACTUAL CIC

Notes to the Financial Statements

for the Period Ended 31 July 2023

3. Tangible assets

Land & buildings Plant & machinery Fixtures & fittings Office equipment Motor vehicles Total
Cost £ £ £ £ £ £
At 1 August 2022 839 839
Additions 651 651
Disposals
Revaluations
Transfers
At 31 July 2023 1,490 1,490
Depreciation
At 1 August 2022 23 23
Charge for year 334 334
On disposals
Other adjustments
At 31 July 2023 357 357
Net book value
At 31 July 2023 1,133 1,133
At 31 July 2022 816 816

TRANSACTUAL CIC

Notes to the Financial Statements

for the Period Ended 31 July 2023

4. Debtors

2023 2022
£ £
Trade debtors 1,750 350
Total 1,750 350

TRANSACTUAL CIC

Notes to the Financial Statements

for the Period Ended 31 July 2023

5. Creditors: amounts falling due within one year note

2023 2022
£ £
Trade creditors 352 13,126
Taxation and social security 4,460 520
Other creditors 18,980 24,161
Total 23,792 37,807

TRANSACTUAL CIC

Notes to the Financial Statements

for the Period Ended 31 July 2023

6. Financial Commitments

The following grants were received over the course of the financial year:Stonewall - Transforming Futures - £20,500LGBT Consortium - Trans Wiki Development - £1,000LGBT Consortium - Equity Fund - £10,000£17,780 of the Stonewall Grant and the LGBT Consortium Trans Wiki Development Grant were for projects starting in the new financial year.

COMMUNITY INTEREST ANNUAL REPORT

TRANSACTUAL CIC

Company Number: 12772196 (England and Wales)

Year Ending: 31 July 2023

Company activities and impact

The Company used grant funding to employ a part-time Director of Operations, which provided The Company with the capacity to expand upon previous work and to plan for the future. Grant funding was also used to employ a part-time Healthcare Programmes Officer, to allow for healthcare specific programme delivery – this grant funding continues into the next financial year, with most deliverables due early in 2024.The Company continued to update its website and social media channels with current and relevant information for trans people, non-binary people, service providers and policy makers.The Company made a number of consultation responses on matters relating to trans and non-binary people and provided evidence to the United Nations Independent Expert on Sexual Orientation and Gender Identity when he visited the UK.The Company retained and further developed its reputation for providing well informed, properly researched and accessible information for trans and non-binary people, allies and policy makers, and continued to co-ordinate the UK’s Trans Health Forum.The Company continued to support and campaign for those impacted by issues with NHS phalloplasty & metoidioplasty, running an online peer support group for those affected.The Company published the ‘Transition Access Survey Report’, which detailed the results of a survey of more than 1,000 trans people into their experiences of medical transition and offered a number of policy recommendations.The Company attended a number of conferences and speaking events over the year.The Company ran a programme of free workshops for trans people, focussed on seeking support from their GP and on legal rights and protections.The Company published a set of healthcare-focussed website articles, written by trans and non-binary people who face multiple barriers to accessing healthcare.The Company delivered a webinar for healthcare professionals working within Primary Care and delivered training and consultancy for a number of healthcare providers and healthcare-focussed organisations.

Consultation with stakeholders

The Company holds regular meetings with volunteers throughout the year to discuss work programmes, particularly around healthcare and possible legislative reform. Work plans are developed in conjunction with these volunteer groups.In the autumn of 2022, the Company published its report into the findings of a survey of over 1,000 trans people in relation to medical transition. The report has been widely cited within professional publications and by professional bodies.In May 2023, the Company commissioned research into the experiences of trans people when seeking healthcare. The report, which will be published in the spring of 2024, will offer guidance on what healthcare professionals can do to ensure that their practice is trans inclusive and supportive.

Directors' remuneration

Directors’ remuneration and related party transactions are detailed in the filed accounts for 2022/23.There were no other transactions or arrangements in connection with the remuneration of directors, or compensation for director’s loss of office, which require to be disclosed

Transfer of assets

Donations of £121 were made to the Kenyan Refugee Trans Initiative which was in line with donations received by the Company specifically for that purpose.

This report was approved by the board of directors on
5 April 2024

And signed on behalf of the board by:
Name: Helen Belcher
Status: Director